Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine.
24/7 Wall St. on MSN2h
I Was Convinced Biotech Stocks Were Too Risky—This Innovation’s Changing the GameThe biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it's really tough to gauge which innovative biotech firms will have something genuinely ground ...
Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical ...
Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...
From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.
7h
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as ...
IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...
Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without ...
Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical ...
The global Human Growth Hormone Powder Injection market is poised for immense growth, propelled by a surge in chronic diseases and the increasing prevalence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback